tyoutyo.com | Gypsum and Platform
tyoutyo.com | Gypsum and Platform
Trump also argued that he is immune from January 6-related prosecutions based on the Constitution’s text for the impeachment process. One provision describes the punishments that Congress can levy upon a person if it impeaches and convicts them: “Judgment in Continue reading The Supreme Court Just Got Dragged Into the Trump Trials
“Demeanor means a lot in this institution, because demeanor generally dictates confidence,” said Representative Richard Neal. “I think that he’s got confidence in himself, and we’ve got confidence in him.” The contrast between McCarthy and Jeffries was established the first Continue reading Hakeem Jeffries Is the Big Winner in the McCarthy Trials
The sixth case, which is scheduled to start the same month as the insurrection case, on March 25, is the Stormy Daniels hush-money case. Now, this matter is generally considered the weakest of the group because a payment like the Continue reading Rejoice, America: These Trials Should Bring
Donald Trump to Ruin
Let’s begin with the states; they are raring to go. Texas, for example, seems to regard Supreme Court decisions as mild suggestions. In 2021, its SB 8 abortion bill didn’t merely test the boundaries of Roe v. Wade but successfully Continue reading How Badly Will the Media Botch the Trump Trials?
Willis’s proposed start date was March 4, 2024, but that would now overlap with Trump’s D.C. federal trial. Further complicating that plan are motions for a speedy trial filed earlier his month by Kenneth Chesebro and Sidney Powell, two of Continue reading Four Trials and a Primary: Here’s What Trump’s Weirdest Campaign Might Look Like
Truth is about power; and lying isn’t lying if it strengthens the movement. The ultimate goal in fascist truth, then, is not to have the best, empirically viable facts. The goal is to demonstrate authenticity and commitment to the movement—to Continue reading Trump’s Trials Don’t Interrupt His Campaign—They
Are His Campaign
CNN — An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday. Gantenerumab is part of a class of Continue reading Experimental therapy gantenerumab fails to slow or improve Alzheimer’s memory loss in clinical trials